Edition:
United States

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

1.50USD
19 Oct 2018
Change (% chg)

$0.05 (+3.45%)
Prev Close
$1.45
Open
$1.45
Day's High
$1.56
Day's Low
$1.43
Volume
8,882
Avg. Vol
23,663
52-wk High
$5.92
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Sonoma Pharma Inc Files For Offering Of Up To $6.0 Mln Of Common Stock
Friday, 12 Oct 2018 05:17pm EDT 

Oct 12 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO $6.0 MILLION OF COMMON STOCK - SEC FILING.  Full Article

Sonoma Pharmaceuticals Announces Results From Study Of HOCL
Tuesday, 28 Aug 2018 07:05am EDT 

Aug 28 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES RESULTS FROM STUDY OF SONOMA’S PERFORMANCE-STABILIZED HOCL™ (HYPOCHLOROUS ACID) IN MANAGEMENT OF ACNE VULGARIS.SONOMA PHARMACEUTICALS -PERFORMANCE-STABILIZED HOCL AS PART OF ACNE MANAGEMENT REGIMEN WILL BECOME AVAILABLE IN U.S. IN WINTER OF 2018.SONOMA PHARMACEUTICALS - NEW HOCL PRODUCTS SHOW "SIGNIFICANT" EFFICACY IN TREATMENT OF MILD-TO-MODERATE ACNE.SONOMA PHARMACEUTICALS INC - BOTH GEL AND SOLUTION OF HOCI WERE EXTREMELY WELL TOLERATED.SONOMA PHARMACEUTICALS - PLANS TO INVESTIGATE EFFICACY OF HOCL ON MODERATE TO SEVERE ACNE VULGARIS.  Full Article

Sonoma Pharmaceuticals Closes $5 Million Public Offering
Tuesday, 6 Mar 2018 07:26pm EST 

March 6 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES CLOSING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK.SONOMA PHARMACEUTICALS INC - ‍ANNOUNCED CLOSING OF PUBLIC OFFERING OF 1,428,570 SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE OF $3.50 PER SHARE.  Full Article

Sonoma Pharmaceuticals Announces Pricing Of $5 Mln Public Offering Of Common Stock
Friday, 2 Mar 2018 08:00am EST 

March 2 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK.SONOMA PHARMACEUTICALS - PRICING OF "BEST EFFORTS" PUBLIC OFFERING OF UP TO 1.4 MILLION SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $3.50/SHARE.  Full Article

Sonoma Pharma Revenue $4.8 Million For Third Quarter
Wednesday, 7 Feb 2018 04:05pm EST 

Feb 7 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS REPORTS RECORD TOTAL REVENUE OF $4.8 MILLION FOR THIRD QUARTER FY 2018 WITH YEAR OVER YEAR PRODUCT REVENUE GROWTH OF 46%.Q3 REVENUE $4.8 MILLION.QTRLY LOSS EARNINGS PER SHARE FROM CONTINUING OPERATIONS $0.73.  Full Article

Sonoma Pharma Gets Three New UAE Regulatory Approvals
Tuesday, 9 Jan 2018 07:05am EST 

Jan 9 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS.SONOMA PHARMACEUTICALS INC - ANTICIPATE LAUNCHING ALL THREE PRODUCTS ACROSS UNITED ARAB EMIRATES IN FEBRUARY 2018.  Full Article

Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products
Tuesday, 5 Dec 2017 07:05am EST 

Dec 5 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS.  Full Article

Sonoma Pharmaceuticals announces FDA approval of expanded indication for Alevicyn
Thursday, 16 Nov 2017 07:45am EST 

Nov 16 (Reuters) - Sonoma Pharmaceuticals Inc ::Announces FDA approval of expanded indication for Alevicyn to add antimicrobial language.Approved Alevicyn dermal spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms​.  Full Article

Sonoma Pharmaceuticals posts Q2 loss $‍0.67/shr from continuing operations​
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals reports robust top line growth for second quarter FY 2018 with 61 pct product revenue growth and total revenue of $4.3 million.Q2 revenue $4.3 million versus $2.8 million.Sonoma Pharmaceuticals qtrly loss per share from continuing operations​ $‍0.67.  Full Article

Sonoma Pharmaceuticals receives Brazilian approvals
Tuesday, 31 Oct 2017 07:45am EDT 

Oct 31 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals receives Brazilian approvals to market multiple hypochlorous acid-based dermatology products.Sonoma Pharmaceuticals Inc - ‍is currently seeking to partner with a Brazilian healthcare co relative to licensing newly approved products.Sonoma Pharmaceuticals Inc - ‍issuance of regulatory approvals by Brazilian Ministério Da Saúde for 7 of co's dermatology products​.  Full Article